| AOM | Azoxymethane |
| AMPK | AMP-activated protein kinase |
| CD | Crohn’s disease |
| CRP | C-reactive protein |
| DPP-4 | Dipeptidyl peptidase-4 |
| DSS | Dextran sulfate sodium |
| FAERS | FDA Adverse Event Reporting System |
| GLP-1 | Glucagon-like peptide-1 |
| GLP-1RA | Glucagon-like peptide-1 receptor agonist |
| GLP-2 | Glucagon-like peptide-2 |
| GSD-Ib | Glycogen storage disease type Ib |
| IBD | Inflammatory bowel disease |
| IL | Interleukin |
| ILC3 | Group 3 innate lymphoid cells |
| LCA | Lithocholic acid |
| LDH | Lactate dehydrogenase |
| LLT | Lower-level term |
| LPS | Lipopolysaccharide |
| MedDRA | Inflammatory bowel disease |
| MPO | Myeloperoxidase |
| NF-κB | Nuclear factor kappa B |
| NLRP3 | NOD-like receptor family pyrin domain containing 3 |
| NO | Nitric oxide |
| PI3K | Phosphoinositide 3-kinase |
| PT | Preferred term |
| ROR | Reporting odds ratio |
| STAT3 | Signal transducer and activator of transcription 3 |
| T2DM | Type 2 diabetes mellitus |
| TGF-β1 | Transforming growth factor beta 1 |
| TGR5 | Takeda G protein-coupled receptor 5 |
| TNF-α | Tumor necrosis factor alpha |
| UC | Ulcerative colitis |